The group's principle activity is to focus on acquisition, clinical development and rapid commercialization of human therapeutics in the Neurology area. The group also develops three clinical-stage compounds for application in four clinical indications. The group's products include AST-726, AST-117, and AST-914. The group operates from United States.
